The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress two of its bispecific ADC programmes to ...
Financing co-led by Frazier Life Sciences and Novartis Venture Fund with significant participation from OrbiMed, Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood ...
Sidewinder Therapeutics’ bispecific antibody-drug conjugates target pairs of receptors found on cancer cells, which the ...
Backed by OrbiMed, Novartis’ venture arm and many other investors, the biotech is among those working on newer technology ...
Three years after its OrbiMed-backed series A in 2023, Sidewinder Therapeutics is adding to its nest egg courtesy of a clutch ...
Sidewinder Therapeutics raises $137M Series B to develop bispecific ADCs for solid tumours and expand clinical pipeline ...
Artillery SideWinder X2 - Unleashing Creativity and Precision Discount Code: 50X2ZB ($50 off) Welcome to our channel! In this ...
US biotech Sidewinder Therapeutics has secured $137 million in an oversubscribed series B financing to advance its bispecific ...
Sunda Energy PLC (AIM:SNDA) this week unveiled a series of strategic developments, including a transformational acquisition ...
The Beijing biotech has been set up to tap into the growing interest in macrocyclic peptides as an emerging treatment ...
The Bahraini advanced F-16 shot down two Iranian drones during the conflict in the Middle East earlier this month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results